Is Collegium Pharmaceutical (COLL) overvalued or fairly valued?

MarketChacha shows Collegium Pharmaceutical's valuation in context — a trailing P/E of about 17.1, a forward P/E of about 4.6, a price-to-book of about 3.6 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Collegium Pharmaceutical's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (4.49×) from reported figures — education, not a rating.

What is Collegium Pharmaceutical's revenue?

Collegium Pharmaceutical reported revenue of $780.6M for FY2025, with net profit of $62.9M, per official filings.

What is the share price of Collegium Pharmaceutical (COLL)?

Collegium Pharmaceutical last traded at $34.85 (-2.8% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

Collegium Pharmaceutical

COLL · NYSE · Healthcare · United States

$34.85-2.8%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 7:30 PM

Snapshot

TickerCOLL

ExchangeNYSE

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

CountryUnited States

Employees423

HeadquartersStoughton, United States

Market cap$1.1B

P/E (TTM)17.1

P/B3.6

Volume120.49K

Websitewww.collegiumpharma.com

Filings tracked6

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Profile as reported by Yahoo Finance.

Who owns it

Insiders1.2%
Institutions98.8%
Public & other0.0%

372 institutional holders

As reported by Yahoo Finance.

Top holders

Blackrock Inc.15.83%
Janus Henderson Group PLC5.63%
Invesco Ltd.4.91%
Fuller & Thaler Asset Management Inc.4.62%
Renaissance Technologies, LLC4.53%
State Street Corporation4.39%
Eventide Asset Management LLC4.39%
Massachusetts Financial Services Co.4.21%

Largest institutional holders, as reported by Yahoo Finance (as of 3/31/2026).

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Cash conversion4.49×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend8.5% → 8.1%

Margin has held broadly steady over the period — stable profitability.

Return on equity20.8%

Latest ROE of 20.8% — capital is generating a healthy return.

Growth qualityrev 17% · PAT 14%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $232.9M · EPS 2.09

Est. earnings growth -7.1%

Next fiscal year

Rev $860.1M · EPS 7.50

Est. earnings growth -3.4%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

$29.1952-wk range$50.79

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Market cap

$1.1B

Day change

-2.8%

P/E (TTM)

17.1

Fwd P/E

4.6

P/B

3.6

Beta

0.73

Revenue (FY2025)

$780.6M

Net margin

8.1%

ROE

20.8%

Revenue CAGR (2y)

+17.4%

Profit CAGR (2y)

+14.3%

EPS (FY2025)

1.73

Net profit (FY2025)

$62.9M

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about COLL

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$780.6M	$62.9M	1.73	8.1%	20.8%
FY2024	$631.4M	$69.2M	1.86	11.0%	30.2%
FY2023	$566.8M	$48.2M	1.29	8.5%	24.6%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q1	$193.5M	$14.5M	0.40	7.5%
2025Q4	$205.4M	$17.0M	0.46	8.3%
2025Q3	$209.4M	$31.5M	0.84	15.0%
2025Q2	$188.0M	$12.0M	0.34	6.4%
2025Q1	$177.8M	$2.4M	0.07	1.4%
2024Q4	$181.9M	$12.5M	0.36	6.9%
2024Q3	$159.3M	$9.3M	0.27	5.9%
2024Q2	$145.3M	$19.6M	0.52	13.5%
2024Q1	$144.9M	$27.7M	0.71	19.1%
2023Q4	$149.7M	$31.9M	0.82	21.3%
2023Q3	$136.7M	$20.6M	0.53	15.1%
2023Q2	$135.5M	$13.0M	0.34	9.6%
2023Q1	$144.8M	$-17.4M	-0.51	-12.0%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K/A — Exhibits
SEC6/30/2026
8-K — Shareholder vote results
SEC5/15/2026material
8-K — Completion of acquisition/disposition, Executive/director change, Reg FD disclosure, Exhibits
SEC5/12/2026material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC5/7/2026material
10-Q filing
SEC5/7/2026
8-K — Executive/director change
SEC4/7/2026material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.